Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp204 | Pituitary Clinical | ECE2018

Long-term efficacy and safety of once-monthly pasireotide in patients with Cushing’s disease: A Phase III extension study

Fleseriu Maria , Petersenn Stephan , Biller Beverly M K , Kadioglu Pinar , De Block Christophe , T'Sjoen Guy , Vantyghem Marie C , Tauchmanova Libuse , Ravichandran Shoba , Roughton Michael , Lacroix Andre , Newell-Price John

Introduction: The 12-month results of a multicentre, double-blind, Phase III study showing the efficacy and safety of a monthly, long-acting formulation of pasireotide in CushingÂ’s disease (CD) patients have been reported previously (Lacroix et al. Lancet Diabetes Endocrinol 2018). The results of the extension phase of this study are reported here.Methods: Patients (n=150) with persistent/recurrent or de novo CD and mean u...